Related Experiment Video

Updated: Aug 26, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Cyclooxygenase-2 inhibitors in glioma therapy

Pierre Giglio1, Victor Levin

  • 1University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA.

American Journal of Therapeutics
|March 5, 2004
PubMed

Insights

Cyclooxygenase-2 (COX-2) inhibitors show promise for treating malignant gliomas. This study explores combining COX-2 inhibitors with retinoids for recurrent glioma treatment, building on celecoxib

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Cyclooxygenase-2 (COX-2) is a prostaglandin synthase enzyme implicated in oncogenesis.
  • COX-2 upregulation is observed in numerous cancer types, suggesting a role in tumor development.
  • Celecoxib (Celebrex), a COX-2 inhibitor, is FDA-approved for familial adenomatous polyposis (FAP) due to polyp reduction.

Purpose of the Study:

  • To investigate the potential therapeutic role of cyclooxygenase-2 (COX-2) inhibitors in treating recurrent malignant gliomas.
  • To evaluate the rationale for combining COX-2 inhibitors with retinoids for malignant glioma treatment.

Main Methods:

  • Review of existing literature on COX-2 inhibitors, retinoids, and malignant gliomas.
  • Analysis of the biological mechanisms underlying COX-2 activity in cancer.
  • Exploration of potential synergistic effects between COX-2 inhibitors and retinoids.

Main Results:

  • The study presents the rationale for a combination therapy approach.
  • Evidence suggests COX-2 inhibitors may impact glioma progression.
  • Retinoids are being investigated for their potential role alongside COX-2 inhibition.

Conclusions:

  • Combination therapy involving COX-2 inhibitors and retinoids warrants further investigation for recurrent malignant gliomas.
  • Understanding the role of COX-2 in gliomagenesis may lead to novel treatment strategies.

More Related Videos

Two-Photon Intravital Microscopy of Glioblastoma in a Murine Model07:25

Two-Photon Intravital Microscopy of Glioblastoma in a Murine Model

Published on: March 1, 2024

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...